Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
Georgina V. Long(The University of Sydney), John M. Kirkwood(UPMC Hillman Cancer Center), Jacob Schachter, Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Thierry Lesimple, Dirk Schadendorf(National Center for Tumor Diseases), Axel Hauschild(University Hospital Schleswig-Holstein), Pingkuan Zhang(Melanoma Institute Australia), Ruth Plummer(National Health Service), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Richard Kefford(Broad Institute), James Larkin(Trinity College Dublin), Laurent Mortier, Victoria Atkinson(The University of Queensland), Bijoyesh Mookerjee(Novartis (United States)), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University Hospital of Zurich), Andrew Haydon(The Alfred Hospital), Caroline Robert(Institut Gustave Roussy), Ran Ji(Jilin University), Jeff Legos(Novartis (Switzerland)), Mario Mandalà(University of Perugia)
Cited by 1,473
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k